Become a member

Quick Registration

Full Registration Benefits -

Free Homepages for Doctors

Free Homepages for Hospitals

Free Homepages for Medical Conference

Free Homepages for NGO's

Personal Health Record Creation

Access to all Medical Slides

Access to all Jobs & Products Sale

Explore Medindia

Medindia » Press Release » Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies

11/21/2008 General News

SAN MARINO, Calif., Nov. 20 Epeius Biotechnologiesannounced today the results of Phase I/II and II studies of Rexin-G inchemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, aspresented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14thannual meetings held in London UK on November 13-15, 2008. Patients receivedrepeated infusions of Rexin-G i.v. over a period up to 9 months. Analysis ofsafety and efficacy data showed no major toxicity, while documentingsignificant control of tumor growth.

Analysis of efficacy in 42 patients with bone and soft tissue sarcomashowed a dose-response relationship between overall survival and Rexin-G whichwas highly significant. A confirmatory Phase II study in 17 osteosarcomapatients showed a median overall survival greater than seven months; that is,after failing standard chemotherapies. Two patients are disease-free greaterthan 6 months after surgical resection of residual tumors and Rexin-G given asboth neoadjuvant and adjuvant monotherapy. These studies indicate that (i)intravenous Rexin-G is safe and well-tolerated, and (ii) Rexin-G controlstumor growth and improves survival in a dose-dependent manner in patients withchemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceuticalcompany dedicated to the advancement of genetic medicine with the developmentand commercialization of its proprietary targeted delivery systems. To learnmore about Rexin-G and Epeius Biotechnologies' pipeline of proprietarycompounds currently available for clinical development, please visit us athttp://www.epeiusbiotech.com .

*(LOGO 72dpi: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg)

This release was issued on behalf of the above organization bySend2Press(R), a unit of Neotrope(R). http://www.Send2Press.com

SOURCE Epeius Biotechnologies

ReachMD Announces New Strategic Partnership with American Medical Directors Association

South-East Asian Diabetes Summit to open up in India

Comment & Contribute

* Your comment can be maximum of 2500 characters
	I agree to the terms and conditions
Your comments are automatically posted once they are submitted. All comments are however constantly reviewed for spam and irrelevant material (such as product or personal advertisements, email addresses, telephone numbers and website address). Such insertions do not conform to our policy and 'Terms of Use' and are either deleted or edited and republished. Please keep your comments brief and relevant.This section may also have questions seeking help. If you have the information you are welcome to respond, but please ensure that the information so provided is genuine and not misleading.